Pharmacologic inhibition of MEK1/2 reduces lung inflammation without impairing bacterial clearance in experimental Pseudomonas aeruginosa pneumonia

This study was designed to test the therapeutic potential of a MEK1/2 inhibitor (MEKi) in an experimental model of Pseudomonas aeruginosa pneumonia. The study found that treatment with MEKi reduced alveolar neutrophilic inflammation and led to faster recovery of weight compared to carrier-treated mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Matthew E., Gong, Ke-Qin, Eddy, William E., Liles, W. Conrad, Manicone, Anne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583963/
https://www.ncbi.nlm.nih.gov/pubmed/28879065
http://dx.doi.org/10.1186/s41479-017-0037-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583963/
https://www.ncbi.nlm.nih.gov/pubmed/28879065
http://dx.doi.org/10.1186/s41479-017-0037-y

Ejemplares similares